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Introduction {#jdi12611-sec-0005}
============

Diabetic kidney disease (DKD) is one of the most prevalent microvascular complications of diabetes mellitus, as well as the leading cause of end‐stage renal disease[1](#jdi12611-bib-0001){ref-type="ref"}. Based on the finding of elevated urinary albumin excretion, DKD is divided into microalbuminuria and macroalbuminuria[2](#jdi12611-bib-0002){ref-type="ref"}. The presence of microalbuminuria indicates generalized vascular endothelial damage and early atherosclerosis. Additionally, microalbuminuria predisposes patients with diabetes mellitus to developing micro‐ and macrovascular complications, such as nephropathy, myocardial infarction and stroke[3](#jdi12611-bib-0003){ref-type="ref"}.

Adipocyte fatty acid‐binding protein (A‐FABP; also termed fatty acid‐binding protein 4 or adipocyte protein 2), an adipokine, is preferentially produced in and released from adipocytes during differentiation and intracellular lipid accumulation[4](#jdi12611-bib-0004){ref-type="ref"}, [5](#jdi12611-bib-0005){ref-type="ref"}. Since circulating A‐FABP was first described by Xu *et al*.[6](#jdi12611-bib-0006){ref-type="ref"}, accumulating evidence has shown that increased concentrations of circulating A‐FABP contribute to obesity, type 2 diabetes mellitus and metabolic syndrome[7](#jdi12611-bib-0007){ref-type="ref"}, [8](#jdi12611-bib-0008){ref-type="ref"}. In our previous research, A‐FABP deficiency was found to protect mice from diabetes‐induced cardiac injury[9](#jdi12611-bib-0009){ref-type="ref"}. Furthermore, findings from clinical studies suggested that A‐FABP might serve as a serum biomarker for DKD stages and cardiovascular risks in patients with diabetes mellitus[10](#jdi12611-bib-0010){ref-type="ref"}, [11](#jdi12611-bib-0011){ref-type="ref"}.

Our previous epidemiological investigations[12](#jdi12611-bib-0012){ref-type="ref"} revealed the ascending prevalence of microalbuminuria among patients with impaired glucose regulation (IGR) and newly diagnosed type 2 diabetes mellitus, which suggested that DKD developed before blood glucose levels increased to levels that met the standard diagnostic criterion for diabetes mellitus. Hence, it is of great importance to explore the relationship between serum A‐FABP levels and microalbuminuria for the early prevention and diagnosis of DKD and other diabetes‐related cardiovascular diseases. However, few data are available regarding the association of serum A‐FABP levels with microalbuminuria in patients with IGR and newly diagnosed type 2 diabetes mellitus. For a more accurate representation of urine albumin excretion in 24 h, the urinary albumin‐to‐creatinine ratio (UACR) is recommended by the American Kidney Foundation as the screening tool for patients with diabetes mellitus[13](#jdi12611-bib-0013){ref-type="ref"}. Using the UACR to define the presence of microalbuminuria in the present study, we aimed to investigate the relationship between serum A‐FABP levels and microalbuminuria.

Materials and Methods {#jdi12611-sec-0006}
=====================

Participants {#jdi12611-sec-0007}
------------

The present study selected a total of 939 participants with IGR and newly diagnosed type 2 diabetes mellitus from the Shanghai Obesity Study, which investigated the onset and progression of metabolic syndrome and its related diseases[14](#jdi12611-bib-0014){ref-type="ref"}. Every participant presented with preserved kidney function (estimated glomerular filtration rate \[eGFR\] ≥60 mL/min/1.73 m^2^). All of the participants provided clinical data, and completed a standardized questionnaire to collect information on their disease history, medication usage, family history and smoking status. The present study excluded individuals with previously diagnosed type 2 diabetes mellitus, type 1 diabetes mellitus, other specific types of diabetes mellitus, gestational diabetes mellitus, macroalbuminuria, urinary tract infection, severe liver or renal dysfunction, hyperthyroidism or hypothyroidism, tumors, psychiatric disease and a history of cardiovascular disease, as well as those receiving antihypertensive therapy, lipid‐lowering therapy, or replacement therapy with systemic corticosteroids or thyroxine at the time of the study.

The study was carried out in accordance with the Declaration of Helsinki, and was approved by the Ethics Committee of Shanghai Jiao Tong University Affiliated Sixth People\'s Hospital. Written informed consent was provided by all of the participants before enrollment in the present study.

Anthropometric and biochemical assessments {#jdi12611-sec-0008}
------------------------------------------

Every participant underwent examination after at least 10 h of overnight fasting. Details on the measurement of anthropometric parameters, which included bodyweight, height, waist circumference (W) and resting blood pressure (BP), were described previously[14](#jdi12611-bib-0014){ref-type="ref"}. Body mass index (BMI) was calculated as weight in kilograms divided by the square of height in meters.

Biochemical variables, such as fasting plasma glucose (FPG), 2‐h plasma glucose (2hPG), glycated hemoglobin (HbA1c), fasting serum insulin (FINS), total cholesterol (TC), triglyceride (TG), high‐density lipoprotein cholesterol (HDL‐c), low‐density lipoprotein cholesterol, C‐reactive protein (CRP) and serum A‐FABP levels (intra‐ and interassay coefficients of variation of 6.6 and 8.7%, respectively) were detected using the standard methods[14](#jdi12611-bib-0014){ref-type="ref"}, [15](#jdi12611-bib-0015){ref-type="ref"}. Serum creatinine and urinary creatinine were determined by the sarcosine oxidase‐PAP method on a 7600‐120 Hitachi automatic analyzer (Hitachi, Tokyo, Japan). Immunonephelometry was used to detect urinary albumin (BN II System; Siemens, Marburg, Germany). UACR was calculated by dividing the urinary albumin by the urinary creatinine levels. The eGFR was calculated according to the Chronic Kidney Disease Epidemiology Collaboration equation[16](#jdi12611-bib-0016){ref-type="ref"}: eGFR = (141 × minimum \[serum creatinine (mg/dL)/*k*, 1\]^α^ × maximum \[serum creatinine/*k*, 1\] ^−1.209^ × 0.993^age^ × 1.018 \[if women\]); *k* is 0.7 (women) or 0.9 (men); α is −0.329 (women) or −0.411 (men). The insulin resistance index[17](#jdi12611-bib-0017){ref-type="ref"} was calculated by the homeostasis model assessment for insulin resistance (HOMA‐IR): HOMA‐IR = FINS (mU/L) × FPG (mmol/L)/22.5.

Diagnostic criteria {#jdi12611-sec-0009}
-------------------

According to 1999 World Health Organization criteria[18](#jdi12611-bib-0018){ref-type="ref"}, diabetes was diagnosed as FPG ≥7.0 mmol/L and/or 2hPG ≥11.1 mmol/L, and IGR was diagnosed as 6.1 mmol/L ≤ FPG \< 7.0 mmol/L and/or 7.8 mmol/L ≤ 2hPG \< 11.1 mmol/L. Microalbuminuria was defined as a UACR between 30--300 mg/g, and macroalbuminuria was defined as a UACR \>300 mg/g^2^. Current smokers were defined as those who smoked regularly (at least once daily) and/or had smoked for a long time (at least 6 months)[19](#jdi12611-bib-0019){ref-type="ref"}.

Statistical analysis {#jdi12611-sec-0010}
--------------------

All statistical analyses were carried out using the Spss 16.0 statistical software package (SPSS Inc., Chicago, Illinois, USA). The normality of the data distribution was determined by the one‐sample Kolmogorov--Smirnov test. Normally distributed data were expressed in the form of the mean ± standard deviation, whereas skewed data were expressed in the form of the median with interquartile range (25--75%). Categorical variables were expressed as percentages (%). Comparisons between the two groups were carried out using an unpaired Student\'s *t*‐test (normal distribution) or the Mann--Whitney *U*‐test (skewed distribution) for continuous data, and the χ^2^‐test for categorical variables[20](#jdi12611-bib-0020){ref-type="ref"}. Spearman\'s correlation coefficient analyses were carried out to examine the relationships of UACR with other variables. Multiple regression analysis was carried out to identify factors independently affecting UACR with the method of stepwise selection. The probabilities of *F* were used for stepping methods criteria: 0.05 was the cut‐off of entry, and 0.10 was the cut‐off of removal[21](#jdi12611-bib-0021){ref-type="ref"}. The potential affecting factors of UACR, including age, BMI, W, SBP, DBP, HbA1c, HOMA‐IR, TC, TG, HDL‐c, low‐density lipoprotein cholesterol, CRP, eGFR and smoking status, were defined as independent variables. All reported *P*‐values were two‐tailed, of which \<0.05 was considered statistically significant.

Results {#jdi12611-sec-0011}
=======

Clinical characteristics of the study participants {#jdi12611-sec-0012}
--------------------------------------------------

A total of 939 participants with an age range of 23--79 years (median 54.62 years \[interquartile range 48.63--60.01\]), including 436 men and 503 women, were enrolled in the present study. Women showed higher serum A‐FABP levels than men (5.15 ng/mL \[interquartile range 3.58--7.32\] vs 3.46 ng/mL \[2.47--4.89\]; *P* \< 0.001). Compared with men, women had higher levels of TC, HDL‐c, eGFR and UACR (all *P* \< 0.01), but lower levels of BMI, W, systolic BP (SBP), diastolic BP (DBP), FPG and TG (all *P* \< 0.01). In addition, fewer women were current smokers (*P* \< 0.01). There were no sex differences in age and other biochemical parameters (all *P* \> 0.05). Men and women were divided into the subgroups according to the serum A‐FABP levels. The median values of serum A‐FABP levels in men and women were defined as the corresponding cut‐off values, respectively. Participants with high levels of serum A‐FABP showed lower eGFR than those with low levels of serum A‐FABP in both men and women (*P* = 0.002 and *P* \< 0.001, respectively).

The participants diagnosed with microalbuminuria accounted for 8.94% (39) of men, and 7.95% (40) of women. The percentage of participants with microalbuminuria did not differ significantly between men and women (*P* = 0.585). BMI, W, SBP, FPG levels, HOMA‐IR, TG level, CRP levels and UACR were much higher in participants with microalbuminuria than in those with normoalbuminuria, which was observed in both men and women (all *P* \< 0.05). Additionally, men with microalbuminuria had higher levels of HbA1c than men with normoalbuminuria (*P* \< 0.05), and women with microalbuminuria were older and showed higher levels of 2hPG and FINS (both *P* \< 0.05), but lower levels of HDL‐c (*P* \< 0.05) compared with women with normoalbuminuria (Table [1](#jdi12611-tbl-0001){ref-type="table-wrap"}).

###### 

Characteristics of the study participants

  Variable                  Men                       Women                                                                                                                                                                                    
  ------------------------- ------------------------- ------------------------- ---------------------------------------------------------------- ------------------------------------------------------------------- ------------------------- ----------------------------------------------------------------
  IGR/T2DM                  330/106                   305/92                    25/14                                                            418/85[\*\*](#jdi12611-note-0002){ref-type="fn"}                    389/74                    29/11
  Age (years)               55.15 (49.00--60.88)      55.21 (49.01--60.92)      53.65 (48.44--60.46)                                             54.29 (48.11--59.35)                                                54.16 (47.89--59.11)      56.77 (52.40--60.82)[§](#jdi12611-note-0002){ref-type="fn"}
  BMI (kg/m^2^)             24.82 ± 3.06              24.63 ± 2.98              26.75 ± 3.18[‡](#jdi12611-note-0002){ref-type="fn"}              24.23 ± 3.30[\*\*](#jdi12611-note-0002){ref-type="fn"}              24.11 ± 3.28              25.59 ± 3.30[¶](#jdi12611-note-0002){ref-type="fn"}
  W (cm)                    87.75 ± 8.69              87.24 ± 8.59              92.94 ± 8.06[‡](#jdi12611-note-0002){ref-type="fn"}              81.50 ± 9.19[\*\*](#jdi12611-note-0002){ref-type="fn"}              81.14 ± 9.18              85.71 ± 8.20[¶](#jdi12611-note-0002){ref-type="fn"}
  SBP (mmHg)                126.67 (119.33--134.67)   125.33 (119.33--133.33)   130.00 (123.33--140.00)[‡](#jdi12611-note-0002){ref-type="fn"}   121.33 (113.33--130.00)[\*\*](#jdi12611-note-0002){ref-type="fn"}   120.67 (112.67--130.00)   126.33 (118.50--136.67)[¶](#jdi12611-note-0002){ref-type="fn"}
  DBP (mmHg)                80.00 (73.33--84.67)      80.00 (73.33--84.00)      80.00 (77.33--90.00)                                             76.67 (70.00--81.33)[\*\*](#jdi12611-note-0002){ref-type="fn"}      76.67 (70.00--80.67)      80.00 (71.75--85.67)
  UACR (mg/g)               5.83 (4.03--10.79)        5.31 (3.93--8.76)         47.25 (34.47--88.33)[‡](#jdi12611-note-0002){ref-type="fn"}      7.75 (5.13--13.07)[\*\*](#jdi12611-note-0002){ref-type="fn"}        7.00 (5.01--10.90)        58.59 (42.68--119.41)[¶](#jdi12611-note-0002){ref-type="fn"}
  eGFR (mL/min/1.73 m^2^)   96.56 (89.57--103.98)     96.08 (89.41--103.76)     100.89 (92.74--107.08)                                           101.09 (95.50--107.37)[\*\*](#jdi12611-note-0002){ref-type="fn"}    101.22 (95.69--107.12)    100.89 (92.69--107.90)
  FPG (mmol/L)              6.03 (5.35--6.56)         5.98 (5.33--6.52)         6.42 (5.59--7.00)[‡](#jdi12611-note-0002){ref-type="fn"}         5.66 (5.21--6.28)[\*\*](#jdi12611-note-0002){ref-type="fn"}         5.62 (5.17--6.27)         5.96 (5.48--6.43)[§](#jdi12611-note-0002){ref-type="fn"}
  2hPG (mmol/L)             8.82 (8.00--10.55)        7.99 (8.85--10.52)        8.68 (8.06--12.96)                                               8.70 (8.04--9.83)                                                   8.63 (8.00--9.78)         9.25 (8.37--11.19)[§](#jdi12611-note-0002){ref-type="fn"}
  HbA1c (%)                 5.8 (5.5--6.1)            5.8 (5.5--6.1)            6.0 (5.6--6.5)[†](#jdi12611-note-0002){ref-type="fn"}            5.8 (5.5--6.1)                                                      5.8 (5.5--6.1)            5.9 (5.6--6.2)
  FINS (mU/L)               8.31 (5.98--11.80)        8.27 (5.89--11.60)        9.21 (6.62--14.00)                                               9.25 (6.25--12.27)                                                  8.89 (6.04--12.11)        11.53 (9.56--14.62)[¶](#jdi12611-note-0002){ref-type="fn"}
  HOMA‐IR                   2.27 (1.54--3.38)         2.22 (1.50--3.32)         3.08 (1.93--4.04)[†](#jdi12611-note-0002){ref-type="fn"}         2.32 (1.55--3.30)                                                   2.25 (1.50--3.24)         3.16 (2.47--3.82)[¶](#jdi12611-note-0002){ref-type="fn"}
  TC (mmol/L)               5.15 ± 0.96               5.12 ± 0.95               5.42 ± 1.01                                                      5.43 ± 0.96[\*\*](#jdi12611-note-0002){ref-type="fn"}               5.43 ± 0.97               5.46 ± 0.87
  TG (mmol/L)               1.70 (1.13--2.30)         1.64 (1.11--2.18)         2.17 (1.58--4.66)[‡](#jdi12611-note-0002){ref-type="fn"}         1.35 (0.99--1.99)[\*\*](#jdi12611-note-0002){ref-type="fn"}         1.31 (0.97--1.88)         2.03 (1.51--2.51)[¶](#jdi12611-note-0002){ref-type="fn"}
  HDL‐c (mmol/L)            1.22 (1.07--1.41)         1.22 (1.08--1.41)         1.26 (1.03--1.49)                                                1.45 (1.26--1.67)[\*\*](#jdi12611-note-0002){ref-type="fn"}         1.46 (1.28--1.68)         1.35 (1.10--1.47)[¶](#jdi12611-note-0002){ref-type="fn"}
  LDL‐c (mmol/L)            3.31 ± 0.90               3.31 ± 0.89               3.30 ± 0.98                                                      3.39 ± 0.86                                                         3.39 ± 0.86               3.37 ± 0.88
  CRP (mg/L)                0.87 (0.47--1.97)         0.85 (0.45--1.88)         1.23 (0.81--3.10)[‡](#jdi12611-note-0002){ref-type="fn"}         0.86 (0.46--1.74)                                                   0.83 (0.44--1.68)         1.16 (0.73--2.40)[¶](#jdi12611-note-0002){ref-type="fn"}
  Current smoker, *n* (%)   202 (46.33)               185 (46.60)               17 (43.59)                                                       10 (1.99)[\*\*](#jdi12611-note-0002){ref-type="fn"}                 9 (1.94)                  1 (2.50)

Data are mean ± standard deviation, median (interquartile range) or *n* (%). \**P* \< 0.05 vs men; \*\**P* \< 0.01 vs men. ^†^ *P* \< 0.05 vs men with normoalbuminuria; ^‡^ *P* \< 0.01 vs men with normoalbuminuria. ^§^ *P* \< 0.05 vs women with normoalbuminuria; ^¶^ *P* \< 0.01 vs women with NAU. 2hPG, 2‐h plasma glucose; A‐FABP, adipocyte fatty acid binding protein; BMI, body mass index; CRP, C‐reactive protein; DBP, diastolic blood pressure; eGFR, estimated glomerular filtration rate; FINS, fasting serum insulin; FPG, fasting plasma glucose; HbA1c, glycated hemoglobin; HDL‐c, high‐density lipoprotein cholesterol; HOMA‐IR, homeostasis model assessment‐insulin resistance; IGR, impaired glucose regulation; LDL‐c, low‐density lipoprotein cholesterol; SBP, systolic blood pressure; T2DM, type 2 diabetes mellitus; TC, total cholesterol; TG, triglyceride; W, waist circumference; UACR, urinary albumin‐to‐creatinine ratio.
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Comparison of serum A‐FABP levels between participants with microalbuminuria and normoalbuminuria {#jdi12611-sec-0013}
-------------------------------------------------------------------------------------------------

For men, participants with microalbuminuria had higher serum levels of A‐FABP than those with normoalbuminuria (5.41 ng/mL \[3.36--7.71\] vs 3.40 ng/mL \[2.42--4.63\]; *P* \< 0.001). Similar results were observed in women (serum A‐FABP levels of 6.08 ng/mL \[4.83--9.13\] in women with microalbuminuria vs 5.00 ng/mL \[3.44--7.12\] in women with normoalbuminuria; *P* \< 0.001). Despite the significant sex difference in the ratio of participants with IGR to those with newly diagnosed type 2 diabetes mellitus (*P* \< 0.01), there was no difference in serum A‐FABP levels between participants with IGR and those with newly diagnosed type 2 diabetes mellitus for either men or women (both *P* \> 0.05). Serum A‐FABP levels were observed to be higher in participants with microalbuminuria, and this difference was found in men with IGR, men with newly diagnosed type 2 diabetes mellitus, women with IGR and women with newly diagnosed type 2 diabetes mellitus (all *P* \< 0.05; Figure [1](#jdi12611-fig-0001){ref-type="fig"}).

![Subgroup comparisons of serum adipocyte fatty acid‐binding protein (A‐FABP) levels between patients with microalbuminuria and those with normoalbuminuria. Serum A‐FABP levels are expressed as median values with interquartile ranges. IGR, impaired glucose regulation; T2DM, type 2 diabetes mellitus.](JDI-8-582-g001){#jdi12611-fig-0001}

Associations between different variables and UACR {#jdi12611-sec-0014}
-------------------------------------------------

Spearman\'s correlation analyses showed that serum A‐FABP levels were positively associated with UACR in both men and women (*P* = 0.005 and *P* \< 0.001, respectively). In addition, BMI, W, SBP, FPG, 2hPG, HbA1c, HOMA‐IR, TG, CRP and eGFR also showed positive correlations with UACR in both sexes (all *P* \< 0.05). The positive associations of DBP (*P* = 0.031) and TC (*P* \< 0.001) with UACR were observed only in men. In women, age (positive, *P* = 0.004) and HDL‐c levels (negative, *P* = 0.001) were significantly related to UACR (Table [2](#jdi12611-tbl-0002){ref-type="table-wrap"}).

###### 

Spearman\'s correlation analysis of the urinary albumin‐to‐creatinine ratio

  Variable   Men      Women               
  ---------- -------- --------- --------- ---------
  Age        −0.048   0.318     0.127     0.004
  BMI        0.113    0.018     0.163     \<0.001
  W          0.124    0.010     0.202     \<0.001
  SBP        0.251    \<0.001   0.134     0.003
  DBP        0.103    0.031     0.010     0.831
  eGFR       0.188    \<0.001   0.106     0.017
  FPG        0.217    \<0.001   0.120     0.007
  2hPG       0.126    0.009     0.162     \<0.001
  HbA1c      0.217    \<0.001   0.141     0.002
  HOMA‐IR    0.145    0.002     0.196     \<0.001
  TC         0.192    \<0.001   0.034     0.445
  TG         0.138    0.004     0.172     \<0.001
  HDL‐c      0.048    0.317     --0.153   0.001
  LDL‐c      0.082    0.089     0.008     0.864
  CRP        0.143    0.003     0.198     \<0.001
  A‐FABP     0.134    0.005     0.174     \<0.001

2hPG, 2‐h plasma glucose; A‐FABP, adipocyte fatty acid binding protein; BMI, body mass index; CRP, C‐reactive protein; DBP, diastolic blood pressure; eGFR, estimated glomerular filtration rate; FINS, fasting serum insulin; FPG, fasting plasma glucose; HbA1c, glycated hemoglobin; HDL‐c, high‐density lipoprotein cholesterol; HOMA‐IR, homeostasis model assessment‐insulin resistance; IGR, impaired glucose regulation; LDL‐c, low‐density lipoprotein cholesterol; SBP, systolic blood pressure; T2DM, type 2 diabetes mellitus; TC, total cholesterol; TG, triglyceride; W, waist circumference; UACR, urinary albumin‐to‐creatinine ratio.
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Multiple stepwise regression analyses of UACR {#jdi12611-sec-0015}
---------------------------------------------

Multiple stepwise regression analysis defined UACR as a dependent variable and serum A‐FABP levels as one of the independent variables. The additional independent variables included age, BMI, W, SBP, DBP, HbA1c, HOMA‐IR, TC, TG, HDL‐c, low‐density lipoprotein cholesterol, CRP, eGFR and smoking status. The results identified serum A‐FABP levels as an independent and positive factor associated with UACR in both men (standardized β = 0.256, *P* \< 0.001) and women (standardized β = 0.155, *P* = 0.001). The independent and positive relationship between serum A‐FABP levels and UACR remained significant even when the multiple stepwise regression analyses were carried out separately in men with IGR (standardized β = 0.258, *P* \< 0.001), men with newly diagnosed type 2 diabetes mellitus (standardized β = 0.278, *P* = 0.002), women with IGR (standardized β = 0.157, *P* = 0.003) and women with newly diagnosed type 2 diabetes mellitus (standardized β = 0.302, *P* = 0.003; Table [3](#jdi12611-tbl-0003){ref-type="table-wrap"}).

###### 

Multivariate linear regression analysis of the urinary albumin‐to‐creatinine ratio

                                Independent variable   Men     Independent variable   Women                                 
  ----------------------------- ---------------------- ------- ---------------------- --------- -------- -------- --------- -------
  Total                         A‐FABP                 0.256   5.830                  \<0.001   A‐FABP   0.155    3.385     0.001
  Age                           0.137                  2.517   0.012                  Age       0.319    5.239    \<0.001   
  SBP                           0.269                  6.228   \<0.001                SBP       0.092    2.168    0.031     
  eGFR                          0.259                  4.759   \<0.001                eGFR      0.297    4.830    \<0.001   
  HbA1c                         0.137                  3.111   0.002                  HOMA‐IR   0.176    3.893    \<0.001   
                                                                                      HDL‐c     −0.094   −2.151   0.032     
  Impaired glucose regulation   A‐FABP                 0.258   5.048                  \<0.001   A‐FABP   0.157    3.024     0.003
  Age                           0.225                  3.511   0.001                  Age       0.351    5.145    \<0.001   
  SBP                           0.228                  4.522   \<0.001                eGFR      0.319    4.565    \<0.001   
  eGFR                          0.292                  4.559   \<0.001                HOMA‐IR   0.135    2.674    0.008     
  TC                            0.154                  3.061   0.002                  HDL‐c     −0.101   −2.069   0.039     
  CRP                           0.128                  2.562   0.011                                                        
  Type 2 diabetes mellitus      A‐FABP                 0.278   3.244                  0.002     A‐FABP   0.302    3.103     0.003
  SBP                           0.266                  3.093   0.003                  SBP       0.295    3.088    0.003     
  eGFR                          0.303                  3.515   0.001                  HDL‐c     −0.219   −2.253   0.027     

Independent variables originally included: adipocyte fatty acid binding protein (A‐FABP), age, body mass index (BMI), waist circumference (W), systolic blood pressure (SBP), diastolic blood pressure (DBP), estimated glomerular filtration rate (eGFR), glycated hemoglobin (HbA1c), homeostasis model assessment‐insulin resistance (HOMA‐IR), total cholesterol (TC), triglyceride (TG), high‐density lipoprotein cholesterol (HDL‐c), low‐density lipoprotein cholesterol (LDL‐c), C‐reactive protein (CRP) and smoking status.

John Wiley & Sons, Ltd

Discussion {#jdi12611-sec-0016}
==========

In the present study, we observed that hyperglycemic individuals with microalbuminuria showed higher serum levels of A‐FABP, and the serum A‐FABP levels were identified as an independent factor positively associated with the UACR. Despite the significant sex difference in serum A‐FABP levels, the relationship between serum A‐FABP levels and the UACR held true for both men and women.

Accumulating clinical evidence showed that the presence of microalbuminuria was not only an early predictor of deteriorative renal function, but also a dominant risk factor for cardiovascular diseases in patients with diabetes mellitus[2](#jdi12611-bib-0002){ref-type="ref"}. A previous study carried out in the general population also supported an association of microalbuminuria with all‐cause mortality and specifically cardiovascular mortality[22](#jdi12611-bib-0022){ref-type="ref"}. Therefore, screening and diagnosis of microalbuminuria are of great importance for individuals with diabetes, and even those without diabetes, to prevent advanced kidney disease, cardiovascular events and death in the early phase. Clinical investigations discovered that serum A‐FABP levels were much higher in diabetes patients with microalbuminuria and macroalbuminuria than in those with normoalbuminuria[10](#jdi12611-bib-0010){ref-type="ref"}; and across groups of patients with normoalbuminuria, microalbuminuria and macroalbuminuria, serum A‐FABP levels showed an increasing trend[11](#jdi12611-bib-0011){ref-type="ref"}. In line with these clinical findings, the present study was carried out among a hyperglycemic population, and showed that serum A‐FABP levels were increased significantly in participants with microalbuminuria.

Our previous epidemiological study showed that compared with individuals with normal glucose tolerance, individuals with newly diagnosed type 2 diabetes mellitus, even those with prediabetes (IGR), were more likely to develop microalbuminuria[12](#jdi12611-bib-0012){ref-type="ref"}. Nevertheless, there were limited data regarding the relationship between serum A‐FABP levels and microalbuminuria, available only in patients with diabetes. Toruner *et al*.[10](#jdi12611-bib-0010){ref-type="ref"} selected a total of 87 patients with type 2 diabetes mellitus as their study population, and found that serum A‐FABP levels were independently and positively associated with the albumin excretion rate, suggesting an involvement of increased serum A‐FABP levels in the occurrence and development of microalbuminuria among patients with type 2 diabetes mellitus. Furthermore, researchers from Hong Kong[11](#jdi12611-bib-0011){ref-type="ref"} also observed that, among patients with diabetes mellitus, serum A‐FABP levels were shown to be independently associated with the severity of nephropathy for micro‐ and macroalbuminuria vs normoalbuminuria, respectively. Their findings raised the possibility that A‐FABP might be used as a serum biomarker for stratifying nephropathy stages in patients with diabetes mellitus. Indirect evidence supporting an association between the serum A‐FABP levels and microalbuminuria was reported by a study carried out in a rural population. In the study of Okazaki *et al*.[23](#jdi12611-bib-0023){ref-type="ref"}, urine A‐FABP levels were correlated with serum A‐FABP levels and UACR, respectively, providing a link between them. However, the overall results have not been entirely consistent. Another study with a small sample size[24](#jdi12611-bib-0024){ref-type="ref"} failed to find a relationship between serum A‐FABP levels and microalbuminuria. After excluding the participants who received antihypertensive or lipid‐lowering therapy at the time of the study to eliminate the influence of such medicines, the present study included, but was not restricted to, individuals with newly diagnosed type 2 diabetes mellitus. Individuals with IGR also were selected for inclusion in the study population. The results showed an independent and positive association between the serum A‐FABP levels and the UACR in this hyperglycemic population. Given these clinical associations, we propose that the serum A‐FABP level can be used as an indicator of microalbuminuria not only in diabetes patients with early stage disease, but also for hyperglycemic individuals before the development of diabetes.

Hsu *et al*.[25](#jdi12611-bib-0025){ref-type="ref"} enrolled 738 normoalbuminuric patients with type 2 diabetes mellitus in their prospective study between 2003 and 2005, and followed them to the end of 2009. They discovered that patients who experienced advanced microalbuminuria had an increased HOMA‐IR at baseline. From the lowest to the highest HOMA‐IR quartiles, the incidences of microalbuminuria increased. Similarly, the present study uncovered a positive correlation between HOMA‐IR and UACR in both sexes. Furthermore, HOMA‐IR was an independent and positive factor associated with UACR in women. The results were suggestive of a critical role for insulin resistance in the onset and progression of microalbuminuria. Based on our previous findings that the serum A‐FABP levels were independently and positively associated with insulin resistance[14](#jdi12611-bib-0014){ref-type="ref"}, [26](#jdi12611-bib-0026){ref-type="ref"}, insulin resistance was implicated as a central factor linking the serum A‐FABP levels and microalbuminuria.

The underlying mechanism through which A‐FABP might contribute to microalbuminuria remains to be determined. Tanaka *et al*.[27](#jdi12611-bib-0027){ref-type="ref"} retrospectively selected a total of 112 consecutive patients who had undergone renal biopsy to subsequently assess the expression of A‐FABP protein and messenger ribonucleic acid, and such expression was finally found not only in peritubular capillaries, but also in endothelial cells and macrophages in the glomerulus. They further discovered that the ratio of the A‐FABP‐positive area to the total area within glomeruli was positively correlated with the urinary protein levels. Macrophage accumulation in the kidney is the origin of inflammation in the progression of nephropathy in patients with diabetes mellitus[11](#jdi12611-bib-0011){ref-type="ref"}. In macrophages, the expression of A‐FABP was mediated by pro‐inflammatory stimuli[28](#jdi12611-bib-0028){ref-type="ref"}, and in turn, modulates the production of inflammatory cytokine[6](#jdi12611-bib-0006){ref-type="ref"}. Thus, it is possible that the ectopic A‐FABP expression in macrophages and inflammation are mutually enhanced in the glomerulus, resulting in renal injury and the onset of microalbuminuria. Additionally, animal studies showed that treatment with an A‐FABP inhibitor improved whole‐body insulin sensitivity of *ob*/*ob* mice[29](#jdi12611-bib-0029){ref-type="ref"}, and targeted disruption of the A‐FABP gene alleviated insulin resistance induced by dietary or genetic obesity in mice[6](#jdi12611-bib-0006){ref-type="ref"}, which suggested that A‐FABP contributed to insulin resistance. Insulin resistance, accompanied by hyperinsulinemia, causes changes in the steady state of renal endothelial functions and hemodynamic harmonization, and eventually leads to the occurrence and progression of microalbuminuria.

The major limitation of the present study was the cross‐sectional design, because it was difficult to clarify the cause--effect relationship between the increase in serum A‐FABP levels and the presence of microalbuminuria. Additionally, the small sample size of the microalbuminuria groups could affect the statistical significance of the results, even though the prevalence of microalbuminuria in individuals with IGR and newly diagnosed type 2 diabetes mellitus was comparable with previously reported values[12](#jdi12611-bib-0012){ref-type="ref"}. Furthermore, given the preserved kidney function in all of the participants, it was difficult to explore the relationship between serum A‐FABP levels and chronic kidney disease stages. Further prospective studies are warranted to confirm and generalize the present findings in a larger population with different chronic kidney disease stages.

In conclusion, the present study showed that in a hyperglycemic population, serum A‐FABP levels increased in the presence of microalbuminuria. In addition, the serum A‐FABP levels were identified as an independent factor positively associated with the UACR.
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